Table 3.
Logistic Regression Modeling Fatigue Worsening for Patients with Baseline Fatigue Level of 0–8 (n=2,367)
| Variable | Univariate regression | Multivariable regression | |||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | P value | OR | 95% CI | P value | ||||
| Demographics | |||||||||
| Age | < 55 v > = 55 | 0.98 | 0.81 | 1.19 | 0.858 | 1.10 | 0.86 | 1.41 | 0.448 |
| Race | Non-Hispanic white v other | 0.95 | 0.80 | 1.13 | 0.564 | 0.96 | 0.79 | 1.16 | 0.673 |
| Disease Characteristics | |||||||||
| Duration of cancer | Continuous (years) | 0.96 | 0.94 | 0.98 | 0.001 | 0.97 | 0.94 | 1.00 | 0.032 |
| Disease status | PD v other | 1.60 | 1.27 | 2.03 | <0.001 | 1.99 | 1.53 | 2.58 | <0.001 |
| Disease site | Colorectal v breast | 0.89 | 0.68 | 1.17 | 0.424 | 0.77 | 0.57 | 1.04 | 0.090 |
| Prostate v breast | 0.91 | 0.62 | 1.33 | 0.633 | 0.93 | 0.59 | 1.45 | 0.744 | |
| Lung v breast | 1.36 | 1.10 | 1.67 | 0.004 | 1.18 | 0.90 | 1.55 | 0.222 | |
| Advanced disease | Yes v no | 1.04 | 0.84 | 1.29 | 0.704 | 0.92 | 0.69 | 1.22 | 0.564 |
| Treatment of Cancer | |||||||||
| Exposure to corticosteroids | Yes v no | 1.55 | 1.21 | 1.98 | 0.001 | 1.37 | 1.03 | 1.83 | 0.031 |
| Current treatment | < 1 m v no treatment | 1.91 | 1.48 | 2.46 | <0.001 | 1.77 | 1.32 | 2.38 | <0.001 |
| > 1 m and <1 yr v no treatment | 1.24 | 0.99 | 1.55 | 0.066 | 1.28 | 0.95 | 1.72 | 0.104 | |
| >1 yr v no treatment | 0.97 | 0.56 | 1.03 | 0.080 | 0.75 | 0.53 | 1.07 | 0.112 | |
| Number of medicines currently taken | 5–9 v 1–4 | 1.29 | 1.04 | 1.59 | 0.018 | 1.18 | 0.91 | 1.52 | 0.203 |
| > = 10 v 1–4 | 1.52 | 1.19 | 1.95 | 0.001 | 1.33 | 0.92 | 1.94 | 0.131 | |
| Missing v 1–4 | 1.44 | 1.05 | 1.97 | 0.022 | 1.26 | 0.91 | 1.73 | 0.158 | |
| Exposure to SSRI/newer antidepressants | Yes v no | 1.33 | 1.10 | 1.60 | 0.003 | 1.29 | 0.99 | 1.68 | 0.055 |
| Exposure to other antidepressants | Yes v no | 0.93 | 0.48 | 1.80 | 0.824 | 0.77 | 0.38 | 1.55 | 0.456 |
| Exposure to anxiolytics | Yes v no | 1.38 | 1.11 | 1.73 | 0.004 | 1.22 | 0.94 | 1.58 | 0.133 |
| Exposure to sedative | Yes v no | 1.04 | 0.76 | 1.43 | 0.790 | 0.83 | 0.57 | 1.20 | 0.319 |
| Exposure to beta blockers | Yes v no | 1.12 | 0.93 | 1.35 | 0.226 | 1.17 | 0.96 | 1.43 | 0.120 |
| Undertreatment of pain | Yes v no | 1.45 | 1.17 | 1.79 | 0.001 | 1.09 | 0.85 | 1.41 | 0.491 |
| Missing v no | 1.13 | 0.67 | 1.91 | 0.648 | 1.13 | 0.61 | 2.11 | 0.699 | |
| Prior chemo/immuno/hormonal therapy | Yes v no | 0.81 | 0.71 | 0.94 | 0.004 | 0.88 | 0.71 | 1.09 | 0.233 |
| Prior radiation | Yes v no | 0.90 | 0.74 | 1.09 | 0.270 | 1.05 | 0.84 | 1.31 | 0.677 |
| Type of institute | Community v academic | 1.01 | 0.73 | 1.39 | 0.968 | 1.17 | 0.72 | 1.91 | 0.533 |
| Receive counseling | Yes v no | 1.14 | 0.86 | 1.51 | 0.373 | 1.08 | 0.73 | 1.58 | 0.701 |
| Participate in support group | Yes v no | 0.74 | 0.51 | 1.07 | 0.111 | 0.77 | 0.52 | 1.14 | 0.187 |
| Quality of Life | |||||||||
| Fatigue at baseline | Continuous | 0.85 | 0.83 | 0.88 | <0.001 | 0.75 | 0.72 | 0.78 | <0.001 |
| History of depression | Yes v no | 1.27 | 1.05 | 1.54 | 0.015 | 1.28 | 1.02 | 1.61 | 0.033 |
| ECOG performance status | > = 1 v 0 | 1.28 | 1.06 | 1.54 | 0.009 | 1.38 | 1.13 | 1.69 | 0.002 |
| Patient's perception of being bothered by comorbidity | Yes v no | 1.12 | 0.94 | 1.33 | 0.224 | 1.26 | 1.03 | 1.54 | 0.028 |
| Clinician's perception of being bothered by comorbidity | Yes v no | 1.10 | 0.90 | 1.33 | 0.370 | 1.14 | 0.87 | 1.49 | 0.346 |
| Patient-reported quality of life | Poor v good | 1.01 | 0.80 | 1.28 | 0.930 | 1.13 | 0.86 | 1.47 | 0.383 |
| Weight loss | > = 5% v < 5% | 1.04 | 0.77 | 1.41 | 0.785 | 1.09 | 0.78 | 1.53 | 0.608 |
| Cognitive difficulty | > = 5 v < 5 | 0.92 | 0.69 | 1.22 | 0.554 | 1.34 | 0.97 | 1.85 | 0.081 |
| Drowsy at baseline | > = 5 v < 5 | 0.67 | 0.53 | 0.86 | 0.002 | 1.03 | 0.74 | 1.44 | 0.852 |
| Sleep at baseline | > = 5 v < 5 | 0.84 | 0.68 | 1.04 | 0.104 | 1.15 | 0.86 | 1.54 | 0.346 |
| Pain at baseline | > = 5 v < 5 | 0.72 | 0.54 | 0.95 | 0.019 | 1.04 | 0.69 | 1.56 | 0.845 |